Potential Molecular Mechanisms behind the Ultra-High Dose Rate "FLASH" Effect.

Int J Mol Sci

Department of Oncology, KU Leuven, 3000 Leuven, Belgium.

Published: October 2022

FLASH radiotherapy, or the delivery of a dose at an ultra-high dose rate (>40 Gy/s), has recently emerged as a promising tool to enhance the therapeutic index in cancer treatment. The remarkable sparing of normal tissues and equivalent tumor control by FLASH irradiation compared to conventional dose rate irradiation—the FLASH effect—has already been demonstrated in several preclinical models and even in a first patient with T-cell cutaneous lymphoma. However, the biological mechanisms responsible for the differential effect produced by FLASH irradiation in normal and cancer cells remain to be elucidated. This is of great importance because a good understanding of the underlying radiobiological mechanisms and characterization of the specific beam parameters is required for a successful clinical translation of FLASH radiotherapy. In this review, we summarize the FLASH investigations performed so far and critically evaluate the current hypotheses explaining the FLASH effect, including oxygen depletion, the production of reactive oxygen species, and an altered immune response. We also propose a new theory that assumes an important role of mitochondria in mediating the normal tissue and tumor response to FLASH dose rates.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9602825PMC
http://dx.doi.org/10.3390/ijms232012109DOI Listing

Publication Analysis

Top Keywords

dose rate
12
ultra-high dose
8
flash
8
flash radiotherapy
8
flash irradiation
8
dose
5
potential molecular
4
molecular mechanisms
4
mechanisms ultra-high
4
rate "flash"
4

Similar Publications

Ciprofol, a novel γ-aminobutyric acid receptor agonist, outperforms propofol with minimal cardiovascular effects, higher potency, reduced injection pain, and a broader safety margin. Despite these advantages, ciprofol's clinical research is still emerging. This study compares the median effective dose (ED) and adverse reactions of ciprofol and propofol, in conjunction with sufentanil, for suppressing cardiovascular responses during tracheal intubation.

View Article and Find Full Text PDF

The Optimal Dosage and Duration of Omega-3 Polyunsaturated Fatty Acid Supplementation in Heart Failure Management: Evidence from a Network Meta-Analysis.

Adv Nutr

January 2025

Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK; Department of Psychiatry & Mind-Body Interface Laboratory (MBI-Lab), China Medical University Hospital, Taichung, Taiwan; College of Medicine, China Medical University, Taichung, Taiwan; An-Nan Hospital, China Medical University, Tainan, Taiwan. Electronic address:

Heart failure is a progressive condition associated with a high mortality rate. Despite advancements in treatment, many patients continue to experience less-than-ideal outcomes. Omega-3 polyunsaturated fatty acids (n-3 PUFAs) have been studied as a potential supplementary therapy for heart failure, but the optimal dosage and duration of supplementation remain unclear.

View Article and Find Full Text PDF

UV-irradiation is a stress factor for proteins, leading to disruption of their native structure. Test systems based on UV-irradiated proteins are relevant for researchers, as they allow working directly with damaged protein molecules, which can be important when studying the properties and mechanisms of action of various antiaggregation agents. The study of UV-irradiated proteins can also have applied significance, including medical.

View Article and Find Full Text PDF

Our previous study revealed that lipid flip-flop inducing phytochemicals from Gymnema sylvestre increase membrane permeability of antimicrobials in S. aureus. However, their lipid flipping and membrane permeabilizing effect on methicillin resistant S.

View Article and Find Full Text PDF

Background: Osimertinib is the standard first-line treatment for advanced epidermal growth factor receptor (EGFR)-mutated NSCLC. However, treatment resistance is inevitable and increased c-Met protein expression correlates with resistance. Telisotuzumab vedotin (Teliso-V) is an antibody-drug conjugate that targets c-Met protein overexpression.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!